AMGN

Amgen Inc. NASDAQ

Healthcare ·Drug Manufacturers - General ·US · amgen.com

$329.82

After hrs $322.00 -0.57%

Mkt Cap $178.8B

52w Low $261.43 52.7% of range 52w High $391.29

50d MA $359.29 200d MA $324.45

P/E (TTM) 23.0x

EV/EBITDA 14.0x

P/B 20.5x

Debt/Equity 6.3x

ROE 89.1%

P/FCF 21.7x

RSI (14) —

ATR (14) —

Beta 0.47

50d MA $359.29

200d MA $324.45

Avg Volume 2.7M

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell coun… Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 30, 2026	AMC	4.77	5.15	+8.0%	346.25	-4.0%	-4.7%	—	—	—	—	—	—
Feb 3, 2026	AMC	4.73	5.29	+11.8%	338.59	+4.0%	+8.2%	+8.6%	+13.5%	+11.0%	+7.7%	+8.6%	—
Nov 4, 2025	AMC	5.02	5.64	+12.4%	296.70	+2.2%	+7.8%	+6.4%	+7.9%	+9.1%	+14.1%	+14.6%	—
Aug 5, 2025	AMC	5.28	6.02	+14.0%	300.08	-1.5%	-5.1%	-5.1%	-3.9%	-5.0%	-5.0%	-6.7%	—
May 1, 2025	AMC	4.27	4.90	+14.8%	283.78	+2.7%	-0.9%	-1.3%	-4.7%	-2.8%	-4.1%	+1.7%	—
Feb 4, 2025	AMC	5.04	5.31	+5.4%	289.02	+0.6%	+6.5%	+3.0%	+1.6%	+2.0%	+2.6%	+10.0%	—
Oct 30, 2024	AMC	5.11	5.58	+9.2%	315.54	+0.7%	+1.5%	+1.2%	+0.4%	+1.2%	+2.0%	-10.4%	—
Aug 6, 2024	AMC	4.98	4.97	-0.2%	328.95	-2.4%	-5.0%	-1.3%	-2.0%	-2.7%	-1.7%	-1.4%	—
May 2, 2024	AMC	3.88	3.96	+2.1%	278.39	+12.6%	+11.8%	+7.6%	+7.9%	+10.4%	+12.4%	+10.4%	—
Feb 6, 2024	AMC	4.59	4.71	+2.6%	316.07	-0.2%	-6.4%	-6.7%	-7.9%	-6.8%	-8.1%	-13.7%	—
Oct 31, 2023	AMC	4.65	4.96	+6.7%	255.70	+0.2%	+2.0%	+4.3%	+5.5%	+6.7%	+6.0%	+5.5%	—
Aug 3, 2023	AMC	4.44	5.00	+12.6%	230.70	+3.1%	+5.5%	+9.6%	+13.0%	+12.4%	+13.6%	+10.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Truist	Maintains	Hold → Hold	—	$346.25	$332.52	-4.0%	-4.7%	—	—	—	—
Apr 21	Canaccord Genuity	Initiates	Hold	$366	$350.16	$350.23	+0.0%	-1.5%	-1.2%	-0.4%	-1.6%	-2.9%
Apr 13	UBS	Maintains	Buy → Buy	—	$351.02	$352.09	+0.3%	-0.3%	-0.0%	-0.8%	-0.5%	+1.2%
Apr 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$355.60	$357.46	+0.5%	-1.3%	-1.6%	-1.3%	-2.1%	-1.7%
Apr 9	Guggenheim	Maintains	Neutral → Neutral	—	$349.81	$347.46	-0.7%	+1.7%	+0.3%	+0.0%	+0.3%	-0.5%
Apr 8	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$340.00	$345.61	+1.6%	+2.9%	+4.6%	+3.2%	+2.9%	+3.2%
Feb 19	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$379.73	$377.91	-0.5%	-1.1%	-1.3%	-0.1%	+0.8%	+1.2%
Feb 18	Piper Sandler	Maintains	Overweight → Overweight	—	$373.36	$373.50	+0.0%	+1.7%	+0.6%	+0.4%	+1.6%	+2.5%
Feb 12	Freedom Broker	Downgrade	Buy → Hold	—	$366.58	$366.66	+0.0%	-0.1%	+0.7%	+1.8%	+3.6%	+2.4%
Feb 6	Guggenheim	Maintains	Neutral → Neutral	—	$367.80	$369.99	+0.6%	+4.5%	+2.2%	-0.9%	-0.3%	-0.4%
Feb 6	Argus	Maintains	Buy → Buy	—	$367.80	$369.99	+0.6%	+4.5%	+2.2%	-0.9%	-0.3%	-0.4%
Feb 4	Leerink Partners	Maintains	Outperform → Outperform	—	$338.59	$352.03	+4.0%	+8.2%	+8.6%	+13.5%	+11.0%	+7.7%
Feb 4	Citigroup	Maintains	Neutral → Neutral	—	$338.59	$352.03	+4.0%	+8.2%	+8.6%	+13.5%	+11.0%	+7.7%
Feb 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$338.59	$352.03	+4.0%	+8.2%	+8.6%	+13.5%	+11.0%	+7.7%
Feb 4	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$338.59	$352.03	+4.0%	+8.2%	+8.6%	+13.5%	+11.0%	+7.7%
Jan 26	UBS	Maintains	Buy → Buy	—	$344.75	$344.70	-0.0%	+1.4%	+1.9%	-0.7%	-0.5%	-0.8%
Jan 20	Bernstein	Downgrade	Outperform → Market Perform	—	$330.41	$325.58	-1.5%	+0.2%	+4.0%	+5.0%	+4.3%	+5.8%
Jan 8	Truist	Maintains	Hold → Hold	—	$341.64	$337.76	-1.1%	-3.4%	-4.5%	-4.7%	-5.1%	-3.7%
Dec 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$317.38	$317.30	-0.0%	+0.1%	+2.5%	+2.9%	+2.7%	+2.2%
Dec 10	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$313.85	$316.25	+0.8%	+0.5%	+1.1%	+1.2%	+3.7%	+4.1%
Dec 3	BMO Capital	Maintains	Outperform → Outperform	—	$338.36	$340.54	+0.6%	+2.1%	+0.5%	-2.5%	-5.1%	-7.2%
Nov 27	Leerink Partners	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—
Nov 14	Piper Sandler	Maintains	Overweight → Overweight	—	$336.00	$336.74	+0.2%	+0.2%	+1.7%	+2.4%	+1.9%	+0.0%
Nov 12	Freedom Broker	Maintains	Hold → Hold	—	$338.45	$338.64	+0.1%	-0.6%	-0.7%	-0.5%	+1.0%	+1.6%
Nov 6	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$319.86	$319.10	-0.2%	-1.3%	+0.1%	+1.2%	+5.8%	+5.1%
Nov 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$296.70	$303.13	+2.2%	+7.8%	+6.4%	+7.9%	+9.1%	+14.1%
Nov 5	Wells Fargo	Maintains	Overweight → Overweight	—	$296.70	$303.13	+2.2%	+7.8%	+6.4%	+7.9%	+9.1%	+14.1%
Sep 26	BofA Securities	Maintains	Underperform → Underperform	—	$271.18	$274.34	+1.2%	+0.7%	+1.0%	+4.1%	+10.1%	+9.7%
Aug 25	Piper Sandler	Maintains	Overweight → Overweight	—	$293.72	$292.61	-0.4%	-1.8%	-1.4%	-2.0%	-2.8%	-2.0%
Aug 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$300.08	$295.51	-1.5%	-5.1%	-5.1%	-3.9%	-5.0%	-5.0%
Aug 6	Citigroup	Maintains	Neutral → Neutral	—	$300.08	$295.51	-1.5%	-5.1%	-5.1%	-3.9%	-5.0%	-5.0%
Aug 6	UBS	Maintains	Neutral → Neutral	—	$300.08	$295.51	-1.5%	-5.1%	-5.1%	-3.9%	-5.0%	-5.0%
Jul 23	BofA Securities	Maintains	Underperform → Underperform	—	$305.69	$307.81	+0.7%	+1.2%	+0.9%	+0.3%	-1.4%	-0.7%
Jul 22	Citigroup	Maintains	Neutral → Neutral	—	$295.87	$296.46	+0.2%	+3.3%	+4.5%	+4.3%	+3.6%	+1.8%
Jul 21	UBS	Maintains	Neutral → Neutral	—	$294.76	$294.75	-0.0%	+0.4%	+3.7%	+4.9%	+4.7%	+4.0%
Jun 27	Piper Sandler	Maintains	Overweight → Overweight	—	$279.11	$278.57	-0.2%	-0.7%	+0.0%	+4.1%	+6.4%	+6.9%
Jun 24	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$272.44	$273.13	+0.3%	+1.9%	+2.9%	+2.4%	+1.7%	+2.5%
May 16	Piper Sandler	Maintains	Overweight → Overweight	—	$271.69	$270.66	-0.4%	+0.3%	+1.5%	+1.2%	-0.1%	+0.1%
May 7	Mizuho	Maintains	Neutral → Neutral	—	$270.44	$272.03	+0.6%	+2.0%	+0.6%	-1.7%	+1.6%	+0.0%
May 2	UBS	Maintains	Neutral → Neutral	—	$283.78	$291.50	+2.7%	-0.9%	-1.3%	-4.7%	-2.8%	-4.1%
May 2	RBC Capital	Maintains	Outperform → Outperform	—	$283.78	$291.50	+2.7%	-0.9%	-1.3%	-4.7%	-2.8%	-4.1%
Apr 14	UBS	Maintains	Neutral → Neutral	—	$285.98	$286.77	+0.3%	+2.8%	+3.3%	-1.2%	-3.0%	-4.3%
Apr 9	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$280.26	$268.91	-4.0%	+3.9%	+0.4%	+2.0%	+4.9%	+5.4%
Mar 5	BofA Securities	Maintains	Underperform → Underperform	—	$312.19	$310.63	-0.5%	+1.4%	+1.8%	+4.1%	+4.9%	+2.1%
Feb 10	Piper Sandler	Maintains	Overweight → Overweight	—	$293.54	$296.88	+1.1%	+0.4%	+1.1%	+0.5%	+1.2%	-0.8%
Feb 6	BofA Securities	Maintains	Underperform → Underperform	—	$307.81	$309.49	+0.5%	-3.3%	-4.6%	-4.2%	-3.6%	-4.1%
Feb 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$289.02	$290.69	+0.6%	+6.5%	+3.0%	+1.6%	+2.0%	+2.6%
Jan 29	BMO Capital	Maintains	Outperform → Outperform	—	$280.30	$280.03	-0.1%	+0.5%	+1.3%	+1.8%	+3.1%	+3.1%
Jan 28	Citigroup	Maintains	Neutral → Neutral	—	$282.95	$280.13	-1.0%	-0.9%	-0.4%	+0.4%	+0.9%	+2.1%
Jan 24	RBC Capital	Maintains	Outperform → Outperform	—	$277.88	$276.26	-0.6%	-0.9%	+1.8%	+0.9%	+1.4%	+2.2%

Recent Filings

8-K · 5.02 !!! Very High

Amgen Inc -- 8-K 5.02: Executive Change

Amgen is redistributing its Chief Technology Officer role among existing executives following Robert Reese's retirement, streamlining leadership structure around science and commercial integration.

Apr 22

8-K · 5.02 !!! Very High

Tivic Health Systems, Inc. -- 8-K 5.02: Executive Change

Tivic Health Systems appointed Michael K. Handley as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction changes and operational impact.

Mar 4

8-K

Amgen Inc -- 8-K Filing

Amgen issued $6 billion in senior notes across four tranches maturing 2031-2056 with rates ranging from 4.2% to 5.65%, providing long-term debt financing at competitive rates.

Feb 19

8-K

Amgen Inc -- 8-K Filing

Amgen uses non-GAAP metrics like adjusted EBITDA and debt leverage ratios to supplement GAAP reporting, allowing investors to better assess operational performance and financial health beyond standard accounting measures.

Feb 3

Data updated apr 24, 2026 5:46pm · Source: massive.com